Published :
Tables : 19
Figures : 31
Category : Healthcare
No. of Pages : 200
Report Code : HC-1058
Fascioliasis Treatment Market Introduction Fascioliasis is a parasitic infection caused by disease transmitted from cattle or sheep through food. This disease is commonly transmitted by consuming aquatic plants like watercress or salad vegetables to which worm cysts are connected, it is also known as 'common liver fluke'. Fascioliasis is caused by two species of parasitic flatworm or trematodes. Fasciola hepatica and Fasciola gigantica trematodes that cause fascioliasis. The diagnosis of fascioliasis is difficult as the parasites are rarely detectable in the initial phase for 9-11 weeks and patients hardly observe any symptoms during that period. The recommended medicine by the World Health Organisation(WHO) is the Triclabendazole that is known to treat fascioliasis in most of the endemic areas in the world. The drug is mainly available through Centres for Disease Control or CDC in the U.S.A. However, this drug is available under investigation protocol as preventive chemotherapy, and awaiting FDA approval in a few states, shown resistance in both livestock and humans. Hence fascioliasis treatment with alternative drugs holds unprecedented importance as this neglected tropical disease can drastically affect public health and cause high morbidity. Fascioliasis Treatment Market Overview High occurrences of fascioliasis cases, global health challenges in controlling food-borne infections, awareness and participation from governing authorities to fight fascioliasis are the global market drivers. The outburst of fascioliasis in wetlands and cattle rearing regions like Vietnam, Egypt, Peru and Bolivia that require hospitalized treatments especially in young children is a major factor causing global fascioliasis treatment market growth. The trudge in research and development of a suitable drug for fascioliasis is another factor that is estimated to boost the market in upcoming years. Government aid and support towards drug development by emerging new manufacturers are also causing significant growth in the market. Factors like appropriate dosage complications, temporary post-treatment side effects and longer treatment cycles are few of the road blockers of the global market. APAC and Latin America are anticipated to grow at a speedy CAGR due to the rise in liver fluke incidences and prevalent dependency on livestock as a food source. Due to strict sanitization norms in Europe and North America Fascioliasis occurrences are negligible resulting in low growth rate. The rest of the world is estimated to grow at a steady pace. Fascioliasis Treatment Market Players: Novartis Animal Health GmbH, Merck Limited, Norbrook Laboratories Ltd, Janssen Pharmaceutica N.V., Pfizer Inc, and so on. Fascioliasis Treatment Market Segmantation By Treatment Type • Standard Therapy • Supportive Therapy By End-User • Hospitals • Clinics • Personalised cares By Region • North America • Latin America • Europe • Asia Pacific • Rest of the World Competitive Landscape: • Tier 1 players- established companies in the market with a major market share • Tier 2 players • Emerging players which are growing rapidly • New Entrants FutureWise Key Takeaways • Growth prospects • SWOT analysis • Key trends • Key data-points affecting market growth Objectives of the Study: • To provide with an exhaustive analysis on the global fascioliasis treatment market on the basis of treatment type, end-user, and region • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) • To evaluate and forecast micro-markets and the overall market • To predict the market size, in key regions (along with countries)—North America, Europe, Asia Pacific, Latin America, and the Middle East • To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions • Profiling of companies to evaluate their market shares, strategies, financials and core competencies
Fascioliasis is a parasitic infection caused by disease transmitted from cattle or sheep through food. This disease is commonly transmitted by consuming aquatic plants like watercress or salad vegetables to which worm cysts are connected, it is also known as 'common liver fluke'. Fascioliasis is caused by two species of parasitic flatworm or trematodes. Fasciola hepatica and Fasciola gigantica trematodes that cause fascioliasis. The diagnosis of fascioliasis is difficult as the parasites are rarely detectable in the initial phase for 9-11 weeks and patients hardly observe any symptoms during that period. The recommended medicine by the World Health Organisation(WHO) is the Triclabendazole that is known to treat fascioliasis in most of the endemic areas in the world. The drug is mainly available through Centres for Disease Control or CDC in the U.S.A. However, this drug is available under investigation protocol as preventive chemotherapy, and awaiting FDA approval in a few states, shown resistance in both livestock and humans. Hence fascioliasis treatment with alternative drugs holds unprecedented importance as this neglected tropical disease can drastically affect public health and cause high morbidity.
Fascioliasis Treatment Market Overview High occurrences of fascioliasis cases, global health challenges in controlling food-borne infections, awareness and participation from governing authorities to fight fascioliasis are the global market drivers. The outburst of fascioliasis in wetlands and cattle rearing regions like Vietnam, Egypt, Peru and Bolivia that require hospitalized treatments especially in young children is a major factor causing global fascioliasis treatment market growth. The trudge in research and development of a suitable drug for fascioliasis is another factor that is estimated to boost the market in upcoming years. Government aid and support towards drug development by emerging new manufacturers are also causing significant growth in the market. Factors like appropriate dosage complications, temporary post-treatment side effects and longer treatment cycles are few of the road blockers of the global market.
APAC and Latin America are anticipated to grow at a speedy CAGR due to the rise in liver fluke incidences and prevalent dependency on livestock as a food source. Due to strict sanitization norms in Europe and North America Fascioliasis occurrences are negligible resulting in low growth rate. The rest of the world is estimated to grow at a steady pace.
Fascioliasis Treatment Market Players:
Novartis Animal Health GmbH, Merck Limited, Norbrook Laboratories Ltd, Janssen Pharmaceutica N.V., Pfizer Inc, and so on.
Fascioliasis Treatment Market Segmantation By Treatment Type • Standard Therapy • Supportive Therapy
By End-User • Hospitals • Clinics • Personalised cares
By Region • North America • Latin America • Europe • Asia Pacific • Rest of the World Competitive Landscape: • Tier 1 players- established companies in the market with a major market share • Tier 2 players • Emerging players which are growing rapidly • New Entrants
FutureWise Key Takeaways
• Growth prospects • SWOT analysis • Key trends • Key data-points affecting market growth
Objectives of the Study:
• To provide with an exhaustive analysis on the global fascioliasis treatment market on the basis of treatment type, end-user, and region • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) • To evaluate and forecast micro-markets and the overall market • To predict the market size, in key regions (along with countries)—North America, Europe, Asia Pacific, Latin America, and the Middle East • To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions • Profiling of companies to evaluate their market shares, strategies, financials and core competencies
Introduction Scope and Objective Assumptions and Acronyms Forecast Factors Research Methodology Executive Summary Industry Cluster Analysis Competition Matrix Strategies Recommendations Market Definition Report Scope (Inclusions & Exclusions) Market Segmentation Fascioliasis Treatment Market Overview Market Revenue (USD Mn) Key Inclusions Porter’s Five Force analysis Market Dynamics Industry Trends Regulatory Guidelines Opportunities in Fascioliasis Treatment Competition Dynamics Company Share Analysis (2020) Top 10 Product Pricing by Region Fascioliasis Treatment Market Revenue (USD Mn), 2020-2027 by Treatment Type Key Market Findings Long Term ROI Segments Revenue Opportunity Influencing Factors Market Revenue (USD Mn) Assessment and Forecast by Treatment Type, 2020-2027 Standard Therapy Supportive Therapy Fascioliasis Treatment Market Revenue (USD Mn), 2020-2027 by End User Key Market Findings Long Term ROI Segments Revenue Opportunity Influencing Factors Market Revenue (USD Mn) Assessment and Forecast by End User, 2020-2027 Hospitals Clinics Personalised care Fascioliasis Treatment Market Revenue (USD Mn), 2020-2027 by Region Key Market Findings Long Term ROI Segments Revenue Opportunity Influencing Factors Market Revenue (USD Mn) Assessment and Forecast by Region,2027 North America Latin America Europe Asia Pacific Rest of world North America Market Revenue (US$ Mn), 2020-2027 Key Market Findings Long Term ROI Segments Revenue Opportunity Influencing Factors Market Revenue (USD Mn) Assessment and Forecast by Country, 2020-2027 US Canada Market Revenue (USD Mn) Assessment and Forecast by Treatment Type, 2020-2027 Standard Therapy Supportive Therapy Market Revenue (USD Mn) Assessment and Forecast by End User, 2020-2027 Hospitals Clinics Personalised care Latin America Market Revenue (US$ Mn), 2020-2027 Key Market Findings Long Term ROI Segments Revenue Opportunity Influencing Factors Market Revenue (USD Mn) Assessment and Forecast by Country, 2020-2027 Brazil Mexico Argentina Rest of Latin America Market Revenue (USD Mn) Assessment and Forecast by Treatment Type, 2020-2027 Standard Therapy Supportive Therapy Market Revenue (USD Mn) Assessment and Forecast by End User, 2020-2027 Hospitals Clinics Personalised care Europe Market Revenue (US$ Mn), 2020-2027 Key Market Findings Long Term ROI Segments Revenue Opportunity Influencing Factors Market Revenue (USD Mn) Assessment and Forecast by Country, 2020-2027 Germany France Spain UK Russia Poland Rest of Europe Market Revenue (USD Mn) Assessment and Forecast by Treatment Type, 2020-2027 Standard Therapy Supportive Therapy Market Revenue (USD Mn) Assessment and Forecast by End User, 2020-2027 Hospitals Clinics Personalised care Asia Pacific Market Revenue (US$ Mn), 2020-2027 Key Market Findings Long Term ROI Segments Revenue Opportunity Influencing Factors Market Revenue (USD Mn) Assessment and Forecast by Country, 2020-2027 Emerging Asia China India ASEAN-5 Rest of Emerging Asia Japan Market Revenue (USD Mn) Assessment and Forecast by Treatment Type, 2020-2027 Standard Therapy Supportive Therapy Market Revenue (USD Mn) Assessment and Forecast by End User, 2020-2027 Hospitals Clinics Personalised care Rest of World Market Revenue (US$ Mn), 2020-2027 Key Market Findings Long Term ROI Segments Revenue Opportunity Influencing Factors Market Revenue (USD Mn) Assessment and Forecast by Country, 2020-2027 Middle East South Africa North Africa Rest of World Market Revenue (USD Mn) Assessment and Forecast by Treatment Type, 2020-2027 Standard Therapy Supportive Therapy Market Revenue (USD Mn) Assessment and Forecast by End User, 2020-2027 Hospitals Clinics Personalised care Company Profiles Competition Landscape Global Company Share (USD Mn) Overview, 2020 Company Profiles Merck Limited Corporate Overview Financial Performance Peer Comparison & 3C marketing equation Company Strategy & Channel Management Novartis Animal Health GmbH Corporate Overview Financial Performance Peer Comparison & 3C marketing equation Company Strategy & Channel Management Norbrook Laboratories Ltd Corporate Overview Financial Performance Peer Comparison & 3C marketing equation Company Strategy & Channel Management Janssen Pharmaceutica N.V. Corporate Overview Financial Performance Peer Comparison & 3C marketing equation Company Strategy & Channel Management Pfizer Inc. Corporate Overview Financial Performance Peer Comparison & 3C marketing equation Company Strategy & Channel Management Research Sources & Primary Verbatim
UK : +44 141 628 9353 US : +1 347 709 4931
OR
Excel Dataset
Infographics
PDF Report
Market Overview
PowerPoint Presentation
Consumer Perception and Procurement
Competitive Analysis
What’s Next
Market Data Forecast
Risks and Opportunity Assessment
Market Trends and Dynamics